Published in J Exp Med on October 01, 1993
Characterization of integrin-tetraspanin adhesion complexes: role of tetraspanins in integrin signaling. J Cell Biol (1999) 2.18
Characterization of novel complexes on the cell surface between integrins and proteins with 4 transmembrane domains (TM4 proteins). Mol Biol Cell (1996) 1.94
Activation of naïve B lymphocytes via CD81, a pathogenetic mechanism for hepatitis C virus-associated B lymphocyte disorders. Proc Natl Acad Sci U S A (2005) 1.76
Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol Biol Cell (2002) 1.69
Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J Exp Med (1997) 1.59
Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell (2012) 1.52
Complement System Part I - Molecular Mechanisms of Activation and Regulation. Front Immunol (2015) 1.52
Impaired CD19 expression and signaling, enhanced antibody response to type II T independent antigen and reduction of B-1 cells in CD81-deficient mice. Proc Natl Acad Sci U S A (1997) 1.42
Complement System Part II: Role in Immunity. Front Immunol (2015) 1.31
Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI3-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization. J Exp Med (1997) 1.25
The 3BP2 adapter protein is required for optimal B-cell activation and thymus-independent type 2 humoral response. Mol Cell Biol (2007) 1.18
Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments. Mol Cell Biol (2006) 1.17
IFITM-Family Proteins: The Cell's First Line of Antiviral Defense. Annu Rev Virol (2014) 1.08
Induction of interleukin-6 after stimulation of human B-cell CD21 by Epstein-Barr virus glycoproteins gp350 and gp220. J Virol (1996) 1.04
The role of complement in the acquired immune response. Immunology (2000) 0.98
Mapping the HLA-DO/HLA-DM complex by FRET and mutagenesis. Proc Natl Acad Sci U S A (2012) 0.97
Complement receptor 2 polymorphisms associated with systemic lupus erythematosus modulate alternative splicing. Genes Immun (2009) 0.96
The absence of Tssc6, a member of the tetraspanin superfamily, does not affect lymphoid development but enhances in vitro T-cell proliferative responses. Mol Cell Biol (2002) 0.96
Comparative functional evolution of human and mouse CR1 and CR2. J Immunol (2008) 0.95
MAL/VIP17, a new player in the regulation of NKCC2 in the kidney. Mol Biol Cell (2010) 0.90
Pathogenetic mechanisms of hepatitis C virus-induced B-cell lymphomagenesis. Clin Dev Immunol (2012) 0.85
Complex N-linked glycans serve as a determinant for exosome/microvesicle cargo recruitment. J Biol Chem (2014) 0.84
Targeting interferon response genes sensitizes aromatase inhibitor resistant breast cancer cells to estrogen-induced cell death. Breast Cancer Res (2015) 0.84
The "ins and outs" of complement-driven immune responses. Immunol Rev (2016) 0.84
Determination of the role for CD21 during Epstein-Barr virus infection of B-lymphoblastoid cells. J Virol (1994) 0.83
Uncoupling CD21 and CD19 of the B-cell coreceptor. Proc Natl Acad Sci U S A (2009) 0.82
EBV Persistence-Introducing the Virus. Curr Top Microbiol Immunol (2015) 0.82
Hepatitis C virus protects human B lymphocytes from Fas-mediated apoptosis via E2-CD81 engagement. PLoS One (2011) 0.81
Atypical Response of B-1 Cells to BCR Ligation: A Speculative Model. Front Immunol (2013) 0.80
Mice expressing human CR1/CD35 have an enhanced humoral immune response to T-dependent antigens but fail to correct the effect of premature human CR2 expression. Immunobiology (2011) 0.80
The contribution of both oxygen and nitrogen intermediates to the intracellular killing mechanisms of C1q-opsonized Listeria monocytogenes by the macrophage-like IC-21 cell line. Immunology (2000) 0.80
Age-related onset of obesity corresponds with metabolic dysregulation and altered microglia morphology in mice deficient for Ifitm proteins. PLoS One (2015) 0.79
A mutation in the human tetraspanin CD81 gene is expressed as a truncated protein but does not enable CD19 maturation and cell surface expression. J Clin Immunol (2015) 0.78
Suppression of innate and adaptive B cell activation pathways by antibody coengagement of FcγRIIb and CD19. MAbs (2014) 0.77
Dengue Virus Directly Stimulates Polyclonal B Cell Activation. PLoS One (2015) 0.76
CD81 interacts with the T cell receptor to suppress signaling. PLoS One (2012) 0.76
Generation of a novel Cr2 gene allele by homologous recombination that abrogates production of Cr2 but is sufficient for expression of Cr1. Immunobiology (2013) 0.75
Pre-stimulation of CD81 expression by resting B cells increases proliferation following EBV infection, but the overexpression of CD81 induces the apoptosis of EBV-transformed B cells. Int J Mol Med (2015) 0.75
Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52
Improved retroviral vectors for gene transfer and expression. Biotechniques (1989) 19.48
Construction and applications of a highly transmissible murine retrovirus shuttle vector. Cell (1984) 13.91
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130. Cell (1989) 5.72
The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol (1988) 5.10
Glycophorin A dimerization is driven by specific interactions between transmembrane alpha-helices. J Biol Chem (1992) 3.52
B4, a human B lymphocyte-associated antigen expressed on normal, mitogen-activated, and malignant B lymphocytes. J Immunol (1983) 3.09
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (1992) 2.79
Antigen receptors on B lymphocytes. Annu Rev Immunol (1992) 2.65
TAPA-1, the target of an antiproliferative antibody, defines a new family of transmembrane proteins. Mol Cell Biol (1990) 2.60
CD21 is a ligand for CD23 and regulates IgE production. Nature (1992) 2.58
B lymphocyte antigen receptors (mIg) are non-covalently associated with a disulfide linked, inducibly phosphorylated glycoprotein complex. EMBO J (1990) 2.24
The CD19/CD21 signal transducing complex of human B lymphocytes includes the target of antiproliferative antibody-1 and Leu-13 molecules. J Immunol (1992) 2.17
Tyrosine phosphorylation of components of the B-cell antigen receptors following receptor crosslinking. Proc Natl Acad Sci U S A (1991) 2.11
Expression of C3d receptors during human B cell differentiation: immunofluorescence analysis with the HB-5 monoclonal antibody. J Immunol (1984) 2.06
Role of transmembrane domain interactions in the assembly of class II MHC molecules. Science (1992) 1.89
CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science (1993) 1.80
Isolation of cDNAs encoding the CD19 antigen of human and mouse B lymphocytes. A new member of the immunoglobulin superfamily. J Immunol (1989) 1.78
Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes. Proc Natl Acad Sci U S A (1991) 1.78
CD19 monoclonal antibody HD37 inhibits anti-immunoglobulin-induced B cell activation and proliferation. J Immunol (1987) 1.76
Selective radiolabeling of cell surface proteins to a high specific activity. Biochemistry (1987) 1.74
In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody. J Exp Med (1990) 1.67
TAPA-1, the target of an antiproliferative antibody, is associated on the cell surface with the Leu-13 antigen. J Immunol (1990) 1.65
Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science (1991) 1.63
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol (1988) 1.62
CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med (1988) 1.60
PMA induces the ligand-independent internalization of CR1 on human neutrophils. J Immunol (1985) 1.51
Structural requirements for C3d,g/Epstein-Barr virus receptor (CR2/CD21) ligand binding, internalization, and viral infection. J Biol Chem (1990) 1.48
Identification of the genes encoding the IgM-alpha and Ig-beta components of the IgM antigen receptor complex by amino-terminal sequencing. Eur J Immunol (1990) 1.39
Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med (1989) 1.35
Monoclonal antibody to the interferon-inducible protein Leu-13 triggers aggregation and inhibits proliferation of leukemic B cells. Blood (1990) 1.22
The sequence of the mu transmembrane segment determines the tissue specificity of the transport of immunoglobulin M to the cell surface. J Exp Med (1990) 1.18
Molecular interactions of complement receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. J Exp Med (1991) 1.17
The CD19 complex of B lymphocytes. Activation of phospholipase C by a protein tyrosine kinase-dependent pathway that can be enhanced by the membrane IgM complex. J Immunol (1991) 1.17
Determination of the structural basis for selective binding of Epstein-Barr virus to human complement receptor type 2. J Exp Med (1991) 1.15
Monovalent ligands of complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell intracytoplasmic free calcium concentration. J Immunol (1990) 1.14
Modulation of mouse complement receptors 1 and 2 suppresses antibody responses in vivo. J Immunol (1991) 1.09
IFN-gamma and IFN-alpha induce the expression and synthesis of Leu 13 antigen by cultured human endothelial cells. J Immunol (1989) 0.98
The lysine residue in the membrane-spanning domain of the beta chain is necessary for cell surface expression of the T cell antigen receptor. J Exp Med (1988) 0.98
Differential effects of the stimulation of complement receptors CR1 (CD35) and CR2 (CD21) on cell proliferation and intracellular Ca2+ mobilization of chronic lymphocytic leukemia B cells. J Immunol (1991) 0.96
Structure and membrane topology of TAPA-1. J Biol Chem (1991) 0.92
Transmembrane signaling of interleukin 2 receptor. Conformation and function of human interleukin 2 receptor (p55)/insulin receptor chimeric molecules. J Exp Med (1987) 0.91
A monoclonal antibody that induces T cell aggregation reacts with vascular endothelial cells and placental trophoblasts. J Immunol (1986) 0.84
Control of the amplification convertase of complement by the plasma protein beta1H. Proc Natl Acad Sci U S A (1976) 6.65
Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A (1984) 6.62
Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med (1980) 6.49
Isolation of a human erythrocyte membrane glycoprotein with decay-accelerating activity for C3 convertases of the complement system. J Immunol (1982) 5.44
Activation of the alternative complement pathway due to resistance of zymosan-bound amplification convertase to endogenous regulatory mechanisms. Proc Natl Acad Sci U S A (1977) 5.23
Regulation of the amplification C3 convertase of human complement by an inhibitory protein isolated from human erythrocyte membrane. Proc Natl Acad Sci U S A (1979) 5.08
Properdin: binding to C3b and stabilization of the C3b-dependent C3 convertase. J Exp Med (1975) 4.69
Soluble human complement receptor type 1: in vivo inhibitor of complement suppressing post-ischemic myocardial inflammation and necrosis. Science (1990) 4.67
Regulation by membrane sialic acid of beta1H-dependent decay-dissociation of amplification C3 convertase of the alternative complement pathway. Proc Natl Acad Sci U S A (1978) 4.43
Genetic diversity and relationships among Streptococcus pyogenes strains expressing serotype M1 protein: recent intercontinental spread of a subclone causing episodes of invasive disease. Infect Immun (1995) 4.40
C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science (1996) 4.35
A unique structure at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II. Proc Natl Acad Sci U S A (1985) 3.98
Formation of a hemolytically active cellular intermediate by the interaction between properdin factors B and D and the activated third component of complement. J Exp Med (1973) 3.83
Increased expression of C3b receptors on polymorphonuclear leukocytes induced by chemotactic factors and by purification procedures. J Immunol (1983) 3.79
Mechanism of suppression of cell-mediated immunity by measles virus. Science (1996) 3.55
Human alternative complement pathway: membrane-associated sialic acid regulates the competition between B and beta1 H for cell-bound C3b. J Immunol (1979) 3.50
Mode of inheritance of decreased C3b receptors on erythrocytes of patients with systemic lupus erythematosus. N Engl J Med (1982) 3.40
Properdin factor D: characterization of its active site and isolation of the precursor form. J Exp Med (1974) 3.21
Activation of the alternative complement pathway with rabbit erythrocytes by circumvention of the regulatory action of endogenous control proteins. J Exp Med (1977) 2.87
Mucoid variation in Pseudomonas aeruginosa induced by the action of phage. J Med Microbiol (1973) 2.82
Action of the C3b-inactivator on the cell-bound C3b. J Immunol (1979) 2.81
CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science (1992) 2.79
Complement ligand-receptor interactions that mediate biological responses. Annu Rev Immunol (1983) 2.78
Marginal zone B cells exhibit unique activation, proliferative and immunoglobulin secretory responses. Eur J Immunol (1997) 2.77
Cloning and sequence analysis of the mouse genomic locus encoding the largest subunit of RNA polymerase II. J Biol Chem (1987) 2.76
Identification of a 145,000 Mr membrane protein as the C3d receptor (CR2) of human B lymphocytes. Proc Natl Acad Sci U S A (1984) 2.71
C1q binds directly and specifically to surface blebs of apoptotic human keratinocytes: complement deficiency and systemic lupus erythematosus revisited. J Immunol (1997) 2.69
A role in B cell activation for CD22 and the protein tyrosine phosphatase SHP. Science (1995) 2.68
C3 nephritic factor (C3NeF): stabilization of fluid phase and cell-bound alternative pathway convertase. J Immunol (1976) 2.64
The CD19/CR2/TAPA-1 complex of B lymphocytes: linking natural to acquired immunity. Annu Rev Immunol (1995) 2.64
Activation of the properdin pathway of complement in patients with gram-negative of bacteremia. N Engl J Med (1975) 2.63
How useful is the UMLS metathesaurus in developing a controlled vocabulary for an automated problem list? Proc Annu Symp Comput Appl Med Care (1993) 2.39
Lipoxygenation of arachidonic acid as a source of polymorphonuclear leukocyte chemotactic factors in synovial fluid and tissue in rheumatoid arthritis and spondyloarthritis. J Clin Invest (1980) 2.37
Membrane distribution and adsorptive endocytosis by C3b receptors on human polymorphonuclear leukocytes. J Exp Med (1981) 2.33
Human C3b/C4b receptor (CR1). Demonstration of long homologous repeating domains that are composed of the short consensus repeats characteristics of C3/C4 binding proteins. J Exp Med (1987) 2.28
Properdin: initiation of alternative complement pathway. Proc Natl Acad Sci U S A (1975) 2.20
Properdin factor D. II. Activation to D by properdin. J Exp Med (1974) 2.19
Purification of C3b inactivator and demonstration of its two polypeptide chain structure. J Immunol (1977) 2.16
Differential effects of vitamin D receptor activators on vascular calcification in uremic rats. Kidney Int (2007) 2.15
Structure and function of the complement receptors, CR1 (CD35) and CR2 (CD21). Adv Immunol (1989) 2.15
Genetic regulation of a structural polymorphism of human C3b receptor. J Clin Invest (1983) 2.07
Current concepts in immunology: the alternative pathway of complement--a system for host resistance to microbial infection. N Engl J Med (1980) 2.07
Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore) (1985) 2.01
Clonal differences within M-types of the group A Streptococcus revealed by pulsed field gel electrophoresis. FEMS Microbiol Lett (1992) 1.97
A complement receptor locus: genes encoding C3b/C4b receptor and C3d/Epstein-Barr virus receptor map to 1q32. J Immunol (1987) 1.94
Initiation of C3 cleavage in the alternative complement pathway. J Immunol (1975) 1.94
Identification of distinct C3b and C4b recognition sites in the human C3b/C4b receptor (CR1, CD35) by deletion mutagenesis. J Exp Med (1988) 1.92
Intersection of the complement and immune systems: a signal transduction complex of the B lymphocyte-containing complement receptor type 2 and CD19. J Exp Med (1991) 1.88
Suppression of signal transducer and activator of transcription 3-dependent B lymphocyte terminal differentiation by BCL-6. J Exp Med (2000) 1.87
A subpopulation of B220+ cells in murine bone marrow does not express CD19 and contains natural killer cell progenitors. J Exp Med (1996) 1.86
Identification of a partial cDNA clone for the human receptor for complement fragments C3b/C4b. Proc Natl Acad Sci U S A (1985) 1.81
CD19 of B cells as a surrogate kinase insert region to bind phosphatidylinositol 3-kinase. Science (1993) 1.80
Lateral distribution and diffusion of the C3b receptor of complement, HLA antigens, and lipid probes in peripheral blood leukocytes. Proc Natl Acad Sci U S A (1980) 1.78
Tyrosine phosphorylation of phospholipase C induced by membrane immunoglobulin in B lymphocytes. Proc Natl Acad Sci U S A (1991) 1.78
Opsonin-independent phagocytosis of activators of the alternative complement pathway by human monocytes. J Immunol (1978) 1.71
Adult forms of the Ca2+ATPase of sarcoplasmic reticulum. Expression in developing skeletal muscle. J Biol Chem (1987) 1.69
A comparison of standard-dose and high-dose epinephrine in cardiac arrest outside the hospital. The Multicenter High-Dose Epinephrine Study Group. N Engl J Med (1992) 1.64
Suppression of the immune response by a soluble complement receptor of B lymphocytes. Science (1991) 1.63
Synergistic interaction between complement receptor type 2 and membrane IgM on B lymphocytes. J Immunol (1988) 1.62
Once-daily amoxicillin versus twice-daily penicillin V in group A beta-haemolytic streptococcal pharyngitis. Arch Dis Child (2008) 1.59
The globular heads of C1q specifically recognize surface blebs of apoptotic vascular endothelial cells. J Immunol (2001) 1.59
Effect of first-responder automated defibrillation on time to therapeutic interventions during out-of-hospital cardiac arrest. The Multicenter High Dose Epinephrine Study Group. Ann Emerg Med (1993) 1.58
Complement receptor 1/CD35 is a receptor for mannan-binding lectin. J Exp Med (2000) 1.56
Identification of a restriction fragment length polymorphism by a CR1 cDNA that correlates with the number of CR1 on erythrocytes. J Exp Med (1986) 1.56
Prospective assessment of C4d deposits on circulating cells and renal tissues in lupus nephritis: a pilot study. Lupus (2011) 1.55
The role of antibody in the activation of the alternative complement pathway. Springer Semin Immunopathol (1983) 1.55
Surface-associated heparin inhibits zymosan-induced activation of the human alternative complement pathway by augmenting the regulatory action of the control proteins on particle-bound C3b. J Exp Med (1979) 1.53
Antibody response to a T-dependent antigen requires B cell expression of complement receptors. J Exp Med (1996) 1.52
PMA induces the ligand-independent internalization of CR1 on human neutrophils. J Immunol (1985) 1.51
C3 requirements for formation of alternative pathway C5 convertase. J Immunol (1976) 1.50
Antigenic diversity within a family of M proteins from group A streptococci: evidence for the role of frameshift and compensatory mutations. Gene (1994) 1.49
Identification of sequence types among the M-nontypeable group A streptococci. J Clin Microbiol (1992) 1.49
Tissue-specific phosphorylation of complement receptors CR1 and CR2. J Exp Med (1986) 1.48
Structure of the human B lymphocyte receptor for C3d and the Epstein-Barr virus and relatedness to other members of the family of C3/C4 binding proteins. J Exp Med (1988) 1.48
Inhibition of the B cell by CD22: a requirement for Lyn. J Exp Med (1998) 1.48
Generation of C3a anaphylatoxin from human C3 by human mast cell tryptase. J Immunol (1983) 1.44
Focal liver lesions: comparison of dual-phase CT and multisequence multiplanar MR imaging including dynamic gadolinium enhancement. J Magn Reson Imaging (2001) 1.43
Identification of a partial cDNA clone for the C3d/Epstein-Barr virus receptor of human B lymphocytes: homology with the receptor for fragments C3b and C4b of the third and fourth components of complement. Proc Natl Acad Sci U S A (1986) 1.42
Decreased expression of the C3b/C4b receptor (CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with systemic lupus erythematosus. Arthritis Rheum (1986) 1.41
Faecal carriage of Pseudomonas aeruginosa by newborn babies. Lancet (1970) 1.41
Lipid monolayer-coated solid surfaces do not perturb the lateral motion and distribution of C3b receptors on neutrophils. J Cell Biol (1982) 1.40
Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes. Proc Natl Acad Sci U S A (1978) 1.39
Isolation of alternative pathway C3 convertase containing uncleaved B and formed in the presence of C3 nephritic factor (C3neF). J Immunol (1976) 1.38
Characterization of a soluble form of the C3b/C4b receptor (CR1) in human plasma. J Immunol (1985) 1.38
Neutrophils express a receptor for iC3b, C3dg, and C3d that is distinct from CR1, CR2, and CR3. J Immunol (1985) 1.37
Seeking wisdom in innate immunity. Nature (1997) 1.37
A soluble divalent class I major histocompatibility complex molecule inhibits alloreactive T cells at nanomolar concentrations. Proc Natl Acad Sci U S A (1993) 1.36
Mapping of the Epstein-Barr virus and C3dg binding sites to a common domain on complement receptor type 2. J Exp Med (1989) 1.35